Gemcabene

• UNSPSC Description:

  Gemcabene (PD-72953), a first-in-class lipid-lowering agent, lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C) and lowers pro-inflammatory acute-phase protein, C-reactive protein (CRP), exerting anti-inflammatory activity[1][2][3].

• Target Antigen:

  Others

• Type:

  Reference compound

• Related Pathways:

  Others

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Metabolic Disease; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/gemcabene.html

• Purity:

  99.91

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C(O)C(C)(C)CCCCOCCCCC(C)(C)C(O)=O

• Molecular Weight:

  302.41

• References & Citations:

  [1]Mandema JW, et al. Model-based development of gemcabene, a new lipid-altering agent. AAPS J. 2005 Oct 7;7(3):E513-22.|[2]Srivastava RAK, et al. Gemcabene, a First-in-Class Hypolipidemic Small Molecule in Clinical Development, Attenuates Osteoarthritis and Pain in Animal Models of Arthritis and Pain. Front Pharmacol. 2018 May 11;9:471.|[3]Oniciu DC, et al. Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM™ model of NASH. PLoS One. 2018 May 30;13(5):e0194568.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Phase 2

• CAS Number:

  183293-82-5